To evaluate the prognostic impact of ST depression resolution among patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI in the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
Introduction
The ECG remains a simple yet powerful tool in the assessment of reperfusion efficacy and prognosis following ST-segment elevation myocardial infarction (STEMI). The current ESC and ACC/AHA guidelines advocate greater than 50% resolution of ST-segment elevation at 60 -90 min following fibrinolysis as a marker of successful reperfusion. 1, 2 This metric is also associated with enhanced myocardial perfusion, recovery of left ventricular function, reduced infarct size, and improved outcomes. 3 -6 Contemporary studies have also affirmed the prognostic utility of ST-segment elevation resolution following primary PCI independent of procedural outcome and final TIMI flow grade in the culprit artery. 7 -11 Less attention has been given towards the evolution of concomitant ST-segment depression in patients with STEMI. Despite uncertainty as to its mechanism, concomitant ST-segment depression has been associated with poorer clinical outcomes. 12 -15 It is recognized from the work of Schroder et al. and others that the extent of ST-segment deviation (elevation plus depression) defines the territory at risk and its overall resolution is prognostically relevant. 3, 4, 10, 16, 17 However, it remains unclear whether reso- prognosis, independent of ST-segment elevation resolution. Accordingly, we examined this issue using core laboratoryassessed ECGs among STEMI patients treated with primary PCI enrolled in the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
Methods
The APEX-AMI trial was a multicenter, randomized, double-blind, placebo-controlled trial of intravenous pexelizumab (a novel humanized monoclonal antibody to C5 complement) in conjunction with primary PCI for patients presenting with acute STEMI. The specific entry criteria have been described previously. 18 Briefly, patients were !18 years old, with symptom onset ,6 h, and had an ECG indicative of acute STEMI that fulfilled any of the following three criteria:
( Since no significant differences were observed in the primary endpoint between the treatment and placebo arms, both arms were pooled for the current analysis.
Electrocardiographic analysis
Standard 12-lead ECGs were obtained at baseline and approximately 30 min post-PCI. All ECGs were evaluated centrally at the ECG core laboratories (Canadian VIGOUR Centre, Edmonton, Canada; Duke Clinical Research Institute, Durham, NC, USA) without knowledge of treatment assignment and outcomes. Examination of the interreader reliability between the two core laboratories revealed 96.0% agreement. ST-segment elevation and depression were measured at the J-point with magnified callipers to the nearest 0.05 mV. The sum total across all leads was used to determine SST depression using an adaptation of Schroder's criteria. 3, 4 Rather than using leads specific to infarct location, we included all leads except aVR. The per cent resolution of SST elevation or SST depression from baseline to 30 min post-PCI was dichotomized in accordance with the ESC and ACC/ AHA guidelines into either !50% or ,50%. 1,2 For purposes of comparison, we also examined resolution of SST-segment deviation (elevationþdepression) using a 50% cut point. 3, 4 Biomarkers of myocardial necrosis (i.e. peak samples of creatine kinase [CK) (U/L), CK-MB (mg/L), troponin-I (mg/L), or troponin-T (mg/L)] were collected and processed according to local protocols. Samples for at least one biomarker for myocardial necrosis were available for all patients in the current study population.
Statistical analysis
Data were reported as percentages for discrete variables and continuous variables as medians with 25th and 75th percentiles with X 2 and
Mann-Whitney U tests for pairwise differences among groups, respectively. Kaplan-Meier survival estimates were used to compare time to the first occurrence of death or the composite of death, cardiogenic shock, or CHF after first balloon inflation and the ST-segment resolution metrics, with pair-wise differences tested using the log-rank test. Multivariable models developed using Cox proportional hazards regression were applied to examine the associations between ST-segment resolution and time to endpoints within 90 days after randomization; adjusted hazard ratios (HR), and corresponding 95% confidence intervals (CI) for the ST-segment resolution metrics are reported. Covariates considered in these models included factors available at randomization (i.e. demographics, medical history, systolic blood pressure, heart rate, Killip class, serum creatinine, and baseline ECG) and those available prior to and including the post-PCI ECG (i.e. time to PCI, complications including major cardiac rhythm disturbances, cardiogenic shock or CHF, angiographic data, and post-PCI ECG).
The importance of the ST-segment resolution factors was assessed by the Schemper and Henderson's 19 V, which is analogous to R 2 in measuring explained variation in linear regression models. Specifically, the marginal proportion of explained variation (PEV) is a measure of the variation due to the factors in the model, whereas the partial PEV measures the decrease in explained variation when removing the prognostic factor of interest. 20 The typical range for overall PEV explained by prognostic factors in survival models is 10 -35%. All hypotheses were determined 'a priori' and as such no adjustments were made for multiple comparisons (i.e. all tests were two-sided, with a 5% level of significance).
All analyses were performed with SAS statistical software (version 9.1.3, SAS Institute, Cary, NC, USA).
Results
Among 5745 patients enrolled in APEX-AMI, 4729 patients constitute our study cohort. Patients excluded were those with missing Figure 1 Kaplan-Meier curves according to ST elevation resolution. (A) 90 day death, log-rank P , 0.001, (B) 90 day death, cardiogenic shock, or CHF, log-rank P , 0.001.
Resolution of ST-segment depression or uninterpretable ECGs (n ¼ 500), those with LBBB (n ¼ 98), and those who did not have ST depression at baseline (n ¼ 418). Hence, the final study cohort consisted of 2123 patients with inferior MI and 2606 patients with non-inferior MI. Table 1 shows baseline and pre-and post-PCI patient characteristics. Data are initially partitioned according to ST elevation resolution (STE-R), then subsequently according to ST depression resolution (STD-R) and both use a 50% cut point. Overall 24% of patients (n ¼ 1143) had STD-R,50%: this occurred more often in patients without STE-R i.e. ,50% (44.4%) vs. those with STE-R!50% (16.4%; P , 0.001). Irrespective of STE-R status, patients with STD-R,50% were more likely to be older, female, diabetic, and have a history of prior CHF. Patients with STD-R,50% were also more likely to have hypertension, a history of prior MI, Killip class .I, and triple vessel disease especially when accompanied by STE-R!50%. There were no significant differences in time from symptom onset to PCI according to STD-R.
Examination of the angiographic procedural outcomes revealed that overall those with STE-R,50% were less likely to have TIMI 3 culprit coronary flow post-PCI when compared with patients with STE-R!50% (80.2 vs. 90.8%; P , 0.001). Irrespective of their STE-R status, patients with STD-R,50% had less frequent TIMI 3 flow post-PCI when compared with those with STD-R!50% especially among the 28% of patients (n ¼ 1313) with STE-R,50%. Whereas no significant differences in peak CK or CKMB measurements were evident across groups, patients with STE-R!50% who had ,50%STD-R tended to have a greater rise in cardiac troponins.
Ninety-day death and the 90 day composite of death, cardiogenic shock or CHF are shown according to STE-R only ( Figure 1A and B) and both STE-R and STD-R (Figure 2A and B) . Compared with patients with STE-R!50%, those with STE-R,50% had higher 90 day mortality ( Figure 1A, 6 .5 vs. 3.1%; P , 0.001) and the 90 day composite ( Figure 1B, 11.6 vs. 5.9%; P , 0.001). Irrespective of STE-R status, patients with STD-R,50% had significantly worse 90 day clinical outcomes when compared with those with STD-R!50% (Figure 2) . Of note among patients with STE-R!50%, the 90 day mortality for those with STD-R,50% was more than twice as high (5.4 vs. 2.6%; P ¼ 0.001). The most favourable outcomes were seen in patients with STE-R and STD-R both !50%, whereas the worst outcomes were evident in the 12% of patients with ,50% STE-R and STD-R. The two groups in whom STE-R and STD-R were discordant (i.e. STE-R!50% and STD-R,50%, or STE-R,50% and STD-R!50%) had similar intermediate outcomes.
Ninety day outcomes according to STE-R and STD-R are presented separately for patients with inferior MI (Figure 3 ) and noninferior MI (Figure 4) . The proportion of patients with STD-R,50% was 22% and 26% among inferior MI and noninferior MI patients, respectively. The worst outcomes were seen in patients with STE-R and STD-R both ,50% (% of total patients, inferior MI: 10%, non-inferior MI: 14%). These patients had a 90 day mortality rate of 8.8% that was identical for those with either inferior or non-inferior MI. Regardless of infarct location, the risk separation afforded by STE-R and STD-R was preserved and generally tracked that of the overall population.
The multivariable-adjusted HR for ST-segment resolution measures in relation to 90 day clinical outcomes (i.e. Model 1: STE-R and STD-R as individual covariates; Model 2: combined STE-R/STD-R; Model 3: Schroder's ST deviation resolution) are presented in Table 2 . As individual covariates, both STE-R and STD-R had comparably strong and independent associations with 90 day mortality and the 90 day composite of death, cardiogenic shock, or CHF ( Table 2 : Model 1). Relative to STE-R, STD-R had a similar or higher marginal PEV (90 day death: 0.57 vs. 0.33%; 90 day composite: 0.63 vs. 0.62%).
When the combination of STE-R and STD-R was examined, a risk gradient was observed with patients experiencing both STE-R and STD-R,50% having a more than two-fold increase in the hazard of dying within 90 days (compared with the reference group of patients with STE-R and STD-R both !50%; adjusted HR 2.54) and experiencing the composite outcome (adjusted HR 2.18; Table 2 : Model 2). Relative to the model with Schroder's ST deviation resolution ( Table 2 : Model 3), the combined STE-R/STD-R had higher partial PEV (90 day death: 1.14 vs. 0.60%, P , 0.0001; 90 day composite: 0.90 vs. 0.53%, P , 0.0001). 
Resolution of ST-segment depression

Discussion
The principal novel finding of this study is that when concomitant ST depression is present in patients with STEMI undergoing primary PCI (representing 92% of the trial population with suitable ECGs), a high risk subset with less than 50% resolution of ST depression after primary PCI exists. This subset constitutes one in four patients with initial ST depression and they experience worse 90 day clinical outcomes. This finding from a large clinical trial of primary PCI in STEMI was independent of baseline co-morbidities, infarct location, TIMI flow grade in the culprit artery, and notably resolution of ST elevation. Hence evaluation of ST depression resolution appears particularly useful in further partitioning risk in patients who achieve apparently successful reperfusion as defined by ST elevation resolution !50%. Among these patients in whom favourable outcomes are generally anticipated, 16% failed to resolve at least 50% of concomitant ST depression and experienced over a two-fold increase in 90 day mortality.
Whereas prior studies have examined resolution of ST depression in the context of ST elevation, they have grouped the changes under the general category of total ST deviation precluding a separate assessment of their relative contribution to outcomes. examined 610 STEMI patients with baseline ST-segment depression and successful primary PCI defined as TIMI 3 flow and !70% ST elevation resolution at 3 h. Less than 70% resolution of ST-segment depression in these patients was associated with larger infarcts and greater 1 year mortality. It remains unclear from these studies whether ST depression resolution retains its prognostic impact independent of ST elevation resolution. Also absent from these studies is whether anatomical infarct location-a strong predictor of outcomes-modulates the impact of ST depression resolution.
Our study complements the previous literature by showing that ST depression resolution retains its prognostic impact irrespective of ST elevation resolution. Specifically, we have shown that after multivariable adjustment, less than 50% resolution of either ST elevation or ST depression had independent and similar risks for 90 day outcomes. Furthermore, ST depression resolution provides significant incremental predictive value to ST elevation resolution in a model that incorporates both metrics discretely. Our study is the first to show that resolution of ST depression retains its prognostic impact irrespective of anatomical infarct location. Importantly, the 90 day mortality was highest and identical (8.8%) among patients with either inferior or non-inferior MI who failed to have at least 50% resolution of either ST elevation or ST depression.
Using data from the APEX-AMI trial, Buller et al. 11 recently demonstrated that overall ST deviation resolution had comparable discriminatory prognostic power when compared with the simpler clinical standard of ST elevation resolution with a 50% cut point. The current study extends these observations by showing that, compared with an approach using overall ST deviation resolution, greater prognostic information is obtained when resolution of ST elevation and ST depression are evaluated as discrete metrics. The mechanism of concomitant ST-segment depression in patients presenting with STEMI continues to be the subject of debate. ST depression may represent: (i) the reciprocal image of ST elevation; 21 -23 (ii) larger, more extensive infarction; 12 -14 (iii) ischaemia beyond the infarcted territory i.e. at a distance; 24, 25 or (iv) posterior wall injury in patients presenting with inferior infarction. 26 , 27 The additional prognostic insight offered by resolution of ST depression supports a pathophysiologic underpinning. We found that patients who failed to resolve ST depression !50% less frequently had post-PCI TIMI 3 flow and a tendency for greater myocardial necrosis based on changes in cardiac troponins. The absence of regional wall motion data precluded an assessment of either posterior wall involvement or myocardial segments beyond the infarcted territory. Failure to resolve !50% of ST depression may represent a proxy for more diffuse coronary artery disease given its association with older age, diabetes, triple vessel disease (among those with !50% ST elevation resolution), and impaired post-PCI TIMI flow in our study. Our study has some limitations. While the ST resolution metrics were statistically significant predictors in the models, their marginal PEVs were relatively modest with respect to the other adjusting factors in the model. The Adjusted for age, systolic BP, heart rate, Killip Class, MI location, serum creatinine, baseline P ST deviation, time from symptom onset to PCI, major cardiac rhythm disturbances, cardiogenic shock or heart failure prior to post-PCI ECG, culprit artery, triple vessel disease, and post-PCI TIMI Flow Grade. b Adjusted for age, sex, hypertension, prior MI, Killip Class, systolic blood pressure, heart rate, baseline P ST deviation, time from symptom onset to PCI, pre-PCI TIMI Flow Grade, culprit artery (LAD, RCA, LCX, and LM/Graft), triple vessel-disease, and post-PCI TIMI Flow Grade. c Based on the method of Schroder et al.
2,3
Resolution of ST-segment depression admissibility criteria as represented by the majority of inferior MI patients having concomitant anterior ST depression. Although our findings may not apply to STEMI patients without these characteristics, they remain broadly applicable since previous registry and clinical trial-based studies have shown that up to two-thirds of inferior MI patients have concomitant anterior ST depression. 28 -30 Not surprisingly, all 418 patients who were excluded from our analysis due to absence of baseline ST depression (7% of the trial population) had non-inferior MI. Because the focus of our study was ST-segment depression and to avoid underestimating its impact, we calculated ST-segment shift from all leads except aVR which departs from the method of Schroder (i.e. taking account of infarct location to determine which leads to include). 3, 4 This is also simpler at the bedside to estimate.
Conclusion
When concomitant ST depression is present in patients with STEMI undergoing primary PCI, less than 50% resolution of ST depression was associated with worse 90 day clinical outcomes even after accounting for the baseline risk profile, infarct location, PCI procedural outcome, and resolution of ST elevation. Although favourable outcomes are generally anticipated in patients with ST elevation resolution !50%, our data indicate that ST depression resolution adds additional important prognostic insight and deserves consideration in the management of these patients and future STEMI guidelines.
